
OBIO Stock Forecast & Price Target
OBIO Analyst Ratings
Bulls say
Orchestra BioMed Holdings Inc. demonstrates a robust investment in its growth through increased expenditures, with SG&A expenses rising by 12% year-over-year to $26.9 million, reflecting its commitment to enhancing operational capabilities. The company's R&D expenditures have also surged, climbing 21% year-over-year to reach $14 million, and projected R&D expenses of $58.2 million for 2025 signal a strong focus on the development of innovative therapies. This strategic emphasis on research and development, paired with risk-reward sharing partnerships, positions the company favorably for successful penetration into targeted markets and potential future revenue growth.
Bears say
Orchestra BioMed Holdings Inc. has consistently reported operating losses since its inception, indicating a lack of financial stability. This ongoing trend of negative financial performance raises concerns about the company’s ability to achieve and sustain profitability in the future. Given these factors, the company's financial outlook remains challenging, with significant risks associated with its business model and developmental stage.
This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
OBIO Analyst Forecast & Price Prediction
Start investing in OBIO
Order type
Buy in
Order amount
Est. shares
0 shares